Menu Search
Equities

Appili Therapeutics Inc

APLIF:PKC

Appili Therapeutics Inc

Actions
  • Price (USD)0.0265
  • Today's Change0.001 / 5.84%
  • Shares traded1.50k
  • 1 Year change-38.47%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 17:34 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.

  • Revenue in CAD (TTM)827.41k
  • Net income in CAD-3.78m
  • Incorporated2015
  • Employees7.00
  • Location
    Appili Therapeutics Inc#21-1344 Summer StreetHALIFAX B3H 0A8CanadaCAN
  • Phone+1 (902) 442-4655
  • Fax+1 (902) 442-4655
  • Websitehttps://appilitherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.